Development of Biodegradable Small Diameter Vascular Graft

Kyohei Oyama
{"title":"Development of Biodegradable Small Diameter Vascular Graft","authors":"Kyohei Oyama","doi":"10.21820/23987073.2023.2.36","DOIUrl":null,"url":null,"abstract":"Coronary heart disease (CHD) is a major cause of death on a global scale. Treatment options include revascularisation, but achieving a successful vascular graft requires using one with a diameter of less than 4mm and there is no artificial vascular graft at such a small diameter available.\n Scientists are interested in developing biodegradable artificial vascular grafts that can help overcome challenges associated with CHD. Associate Professor Kyohei Oyama and his team in the Department of Cardiac Surgery, Asahikawa Medical University, Japan, are currently working on two main\n projects: Creating a biodegradable small diameter vascular graft; and developing a heart regeneration treatment via endogenous cardiac myocyte proliferation. In developing a biodegradable small diameter vascular graft, the researchers hope to benefit patients that require the revascularisation\n of small vessels and also positively impact young patients who are still growing. The team also hope that the discoveries made through this research might lead to advances in other organ regeneration. When it comes to the need to recover lost cardiac tissue, this is unable to regenerate as\n cardiac myocytes (muscle cells) have no ability to proliferate. Oyama and the team are investigating the mechanism that limits this proliferation ability with a view to activating it. If cardiac myocyte proliferation can be activated during the revascularisation of CHD, then the damaged heart\n can be completely cured and the possibility of heart failure eliminated.","PeriodicalId":88895,"journal":{"name":"IMPACT magazine","volume":"98 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IMPACT magazine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21820/23987073.2023.2.36","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Coronary heart disease (CHD) is a major cause of death on a global scale. Treatment options include revascularisation, but achieving a successful vascular graft requires using one with a diameter of less than 4mm and there is no artificial vascular graft at such a small diameter available. Scientists are interested in developing biodegradable artificial vascular grafts that can help overcome challenges associated with CHD. Associate Professor Kyohei Oyama and his team in the Department of Cardiac Surgery, Asahikawa Medical University, Japan, are currently working on two main projects: Creating a biodegradable small diameter vascular graft; and developing a heart regeneration treatment via endogenous cardiac myocyte proliferation. In developing a biodegradable small diameter vascular graft, the researchers hope to benefit patients that require the revascularisation of small vessels and also positively impact young patients who are still growing. The team also hope that the discoveries made through this research might lead to advances in other organ regeneration. When it comes to the need to recover lost cardiac tissue, this is unable to regenerate as cardiac myocytes (muscle cells) have no ability to proliferate. Oyama and the team are investigating the mechanism that limits this proliferation ability with a view to activating it. If cardiac myocyte proliferation can be activated during the revascularisation of CHD, then the damaged heart can be completely cured and the possibility of heart failure eliminated.
可生物降解的小直径血管移植物的研制
冠心病(CHD)是全球范围内的一个主要死亡原因。治疗方法包括血管重建,但成功的血管移植需要使用直径小于4毫米的血管,目前还没有如此小直径的人工血管移植。科学家们对开发可生物降解的人工血管移植物很感兴趣,这种移植物可以帮助克服与冠心病相关的挑战。日本旭川医科大学心脏外科系副教授Kyohei Oyama和他的团队目前正在进行两个主要项目:制造可生物降解的小直径血管移植物;并通过内源性心肌细胞增殖发展心脏再生治疗。在开发可生物降解的小直径血管移植物的过程中,研究人员希望使需要小血管重建的患者受益,并对仍在生长的年轻患者产生积极影响。研究小组还希望通过这项研究取得的发现可能会导致其他器官再生方面的进展。当需要恢复失去的心脏组织时,这是无法再生的,因为心肌细胞(肌肉细胞)没有增殖的能力。Oyama和他的团队正在研究限制这种增殖能力的机制,以期激活它。如果在冠心病的血运重建过程中能够激活心肌细胞增殖,那么受损的心脏就可以完全治愈,消除心力衰竭的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信